Novartis Innovative Therapies AG entered into an amended and restated licensing agreement with 3B Pharmaceuticals GmbH (3BP) for the latter’s fibroblast activation protein (FAP)-targeting peptide technology, the two companies announced Monday morning.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,